In order to improve the interfacial bonding strength of hydroxyapatite/polyurethane implanted material and dispersion of hydroxyapatite in the polyurethane matrix, we in the present study synthesized nano-hydroxyapatite/polyurethane composites by in situ polymerization. We then characterized and analyzed the fracture morphology, thermal stability, glass transition temperature and mechanical properties. We seeded MG63 cells on composites to evaluate the cytocompatibility of the composites. In situ polymerization could improve the interfacial bonding strength, ameliorate dispersion of hydroxyapatite in the properties of the composites. After adding 20 wt% hydroxyapatite into the polyurethane, the thermal stability was improved and the glass transition temperatures were increased. The tensile strength and maximum elongation were 6.83 MPa and 861.17%, respectively. Compared with those of pure polyurethane the tensile strength and maximum elongation increased by 236.45% and 143.30%, respectively. The composites were helpful for cell adhesion and proliferation in cultivation.
Biocompatible Materials ; chemistry ; Cell Adhesion ; Cell Line ; Durapatite ; chemistry ; Humans ; Polymerization ; Polyurethanes ; Tensile Strength ; Transition Temperature

Background and purpose: L-asparaginase (L-Asp) is an important drug in the treatment of childhood lymphoid neoplasms at present, but a lot of adverse reactions of L-Asp were observed. Pegasparaginase (PEG-Asp) is available in China in recent years. This study aimed to explore efifcacy and side-effect of PEG-Asp as ifrst-line treatment in childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Methods:A total number of 211 ALL or LBL patients were treated with CCLG 2008 or BFM-90 protocol with PEG-Asp or L-Asp between Apr. 2008 and Mar. 2013;42 patients, among whom, were 35 ALL patients and 7 LBL patients, were treated with PEG-Asp as ifrst-line treatment;169 patients were treated with L-Asp as ifrst-line treatment (including 53 patients treated with L-Asp during induction protocol; with PEG-Asp during consolidate protocol). The clinical outcome and adverse reaction of PEG-Asp with L-Asp were observe and compared. Results: There were 35 ALL patients in PEG-Asp ifrst-line treatment group and the complete remission rate after 1 course of PEG-Asp was 97.1%,however, which was 83.3%of high risk ALL patients. The complete remission rate of 7 LBL patients of PEG-Asp ifrst-line treatment group was 57.1%. There was no signiifcant difference between 2 groups (P>0.05). Thirty-four patients relapsed including 5 patients of PEG-Asp ifrst-line treatment group, 16 patients of L-Asp ifrst-line treatment group and 13 patients treated with L-Asp during induction protocol and with PEG-Asp during consolidate protocol. Thirty-one patients died including 3, 18, 10 patients in 3 groups respectively. Twenty-two patients died of relapse, 4 died without remission, 5 died of complications. There was also no signiifcant difference between 2 groups (P>0.05). The incidence rates of adverse reactions were 47.6% and 63.3% respectively. Anaphylaxis, liver functions abnormalities, blood coagulation abnormalities, gastrointestinal reaction, hyperglycemia and pancreatitis were common in our patients. The incidence rate of anaphylaxis in PEG-Asp as ifrst-line treatment group was lower than other groups (P=0.03). But there was no signiifcant difference been observed in the incidence of other adverse reaction. Conclusion: The short-term efifcacy of PEG-Asp as the ifrst-line treatment in childhood leukemia and lymphoma was satisfactory and the incidence rate of anaphylaxis was lower. However, we will still pay much attention to adverse reaction monitoring of PEG-Asp.

Objective To evaluate the effect on salvage treatment of sudden deafness with comprehensive Chinese medicine therapy. Methods Fifty-three sudden deafness patients failing in conventional western medicine treatment were given comprehensive Chinese medicine therapy, and the salvage treatment followed by oral use of Chinese medicine, intravenous injection of Chinese patent medicine, acupoint injection, ear acupoint plastering, acupoint application, acupuncture, sound healing, and massage. The therapeutic effect and the relief of major accompanying symptoms were evaluated after treatment, and the relationship of disease course with clinical efficacy was also investigated. Results (1) After treatment, 4 cases were cured, 9 were markedly effective, 13 were effective, 27 were ineffective, and the total effective rate was 49.06%. (2) Except for the 2 excluded cases, the major accompanying symptoms such as tinnitus, auricular distress, and vertigo were relieved to various degrees in other cases. ( 3) Twenty-two patients had a course of disease within 14 days, and the total effective rate for them was 72.73%. A total effective rate of 32.26% was achieved in 31 cases with disease course over 14 days. It is indicated that the therapeutic effect for patients with a disease course less than 14 days was superior to that with a disease course over 14 days (P<0.01). Conclusion Comprehensive Chinese medicine therapy exerts inspiring therapeutic effect on salvage treatment of sudden deafness, and earlier intervention results into better effect.

Objective To evaluate the short-term and long-term effect of comprehensive traditional Chinese medical therapy for regulating spleen and stomach in treating tinnitus. Methods Telephone follow-up was carried out in 333 cases of qualified tinnitus outpatients and inpatients from the First Affiliated Hospital of Guangzhou University of Chinese Medicine admitted from January of 2008 to December of 2014. All of the included patients were treated by comprehensive traditional Chinese medical therapy for regulating spleen and stomach. The degree of tinnitus was evaluated by Tinnitus Effect Questionnaire(TEQ) on the first visit and the last visit and during follow-up, and then the TEQ scores were analyzed by statistical methods. Results On the first visit, the mean TEQ scores were 11.17 ± 3.11. On the last visit, the mean treatment course was 33.64 ± 37.07 days, and the mean TEQ scores were 9.57 ± 3.43; 5 cases were cured, 25 were markedly effective, 79 were effective, 224 were ineffective, and the total effective rate was 32.73%. The interval of the first follow-up to the first visit averaged 32.89 ± 8.53 months, and the mean TEQ scores were 5.35 ± 3.71 during the interval; 20 cases were cured, 21 were markedly effective, 39 were effective, 43 were ineffective, and the total effective rate was 65.04%. The interval of the second follow-up to the first visit averaged 57.48 ± 7.91 months, and the mean TEQ scores were 3.42 ± 3.39 during the interval; 37 cases were cured, 21 were markedly effective, 26 were effective, 39 were ineffective, and the total effective rate was 68.29%. Conclusion Comprehensive traditional Chinese medical therapy for regulating spleen and stomach has certain effect in treating tinnitus, and the long-term effect is satisfactory.

Objective To explore the application value of different preprotein converting subtili-sin/kexin type 9(PCSK9)inhibitors in familial hypercholesterolemia(FH).Methods Patients with FH in our hospital were selected and divided into alirocumab group and evolocumab group according to the different PCSK9 inhibitors after excluding the confounding factors of baseline data such as gen-der and age by propensity score matching,41 patients in each group were matched.Both groups were treated for 3 months.The therapeutic effect,and blood lipids levels[triglyceride(TG),total cholester-ol(TC),low density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)index,apolipoprotein A1(Apo A1),apolipoprotein B(Apo B)],coronary flow reserve[absolute coronary flow reserve(CFR),relative coronary flow reserve(rCFR),fractional flow reserve(FFR)],endothelial function indicators[serum nitric oxide(NO),endothelin-1(ET-1),flow me-diated dilatation(FMD)]and adverse reactions before and after treatment were compared between both groups.Results After three months of treatment,the overall standardized rate of LDL-C in the alirocumab group was 97.56％(40/41),and 92.68％in the evolocumab group,but there was no sta-tistically significant difference between the two groups(P＞0.05).After treatment,the levels of TG,TC,LDL-C,Apo B,and ET-1 in both groups decreased,while the levels of HDL-C,Apo A1,CFR,rCFR,FFR,NO,and FMD increased.Additionally,the levels of TG,TC,LDL-C,Apo B,and ET-1 in the alirocumab group were lower than those in the evolocumab group,while the levels of HDL-C,Apo A1,CFR,rCFR,FFR,NO,and FMD were higher,and the differences were statistically sig-nificant(P＜0.05).The incidence of adverse reactions was 12.20％in the alirocumab group and 9.76％in the evolocumab group,with no statistically significant difference(P＞0.05).Conclu-sion Alirocumab or evolocumab combined with rosuvastatin in treating FH can effectively improve the lipid metabolism,coronary flow reserve function and vascular endothelial function in the treat-ment of patients with hypercholesterolemia,but alirocumab has a better effect.

Objective To explore the application value of different preprotein converting subtili-sin/kexin type 9(PCSK9)inhibitors in familial hypercholesterolemia(FH).Methods Patients with FH in our hospital were selected and divided into alirocumab group and evolocumab group according to the different PCSK9 inhibitors after excluding the confounding factors of baseline data such as gen-der and age by propensity score matching,41 patients in each group were matched.Both groups were treated for 3 months.The therapeutic effect,and blood lipids levels[triglyceride(TG),total cholester-ol(TC),low density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)index,apolipoprotein A1(Apo A1),apolipoprotein B(Apo B)],coronary flow reserve[absolute coronary flow reserve(CFR),relative coronary flow reserve(rCFR),fractional flow reserve(FFR)],endothelial function indicators[serum nitric oxide(NO),endothelin-1(ET-1),flow me-diated dilatation(FMD)]and adverse reactions before and after treatment were compared between both groups.Results After three months of treatment,the overall standardized rate of LDL-C in the alirocumab group was 97.56％(40/41),and 92.68％in the evolocumab group,but there was no sta-tistically significant difference between the two groups(P＞0.05).After treatment,the levels of TG,TC,LDL-C,Apo B,and ET-1 in both groups decreased,while the levels of HDL-C,Apo A1,CFR,rCFR,FFR,NO,and FMD increased.Additionally,the levels of TG,TC,LDL-C,Apo B,and ET-1 in the alirocumab group were lower than those in the evolocumab group,while the levels of HDL-C,Apo A1,CFR,rCFR,FFR,NO,and FMD were higher,and the differences were statistically sig-nificant(P＜0.05).The incidence of adverse reactions was 12.20％in the alirocumab group and 9.76％in the evolocumab group,with no statistically significant difference(P＞0.05).Conclu-sion Alirocumab or evolocumab combined with rosuvastatin in treating FH can effectively improve the lipid metabolism,coronary flow reserve function and vascular endothelial function in the treat-ment of patients with hypercholesterolemia,but alirocumab has a better effect.

Objective To explore the biomarkers associated with angiogenesis-related genes(ARGs)in diabetic reti-nopathy(DR)based on transcriptomics.Methods The differentially expressed genes(DEGs)between the DR patients(DR group)and the healthy population(control group)were identified through differential expression analysis.Weighted gene co-expression network analysis(WGCNA)was used to obtain the key module genes most significantly related to ARGs.Candidate genes were determined by taking the intersection of DEGs and these key module genes obtained.Then,three machine learning algorithms were used to screen potential DR biomarkers from these candidate genes,a nomogram model used for DR diagnosis was constructed based on these biomarkers,and the accuracy of nomogram model prediction was further verified by drawing and analyzing receiver operating characteristic(ROC)curves,calibration curves and deci-sion curve analysis curves.Furthermore,the immune cell infiltration in the DR group and the control group was compared,and the potential biomarker-targeted chemotherapeutics for DR treatment was predicted.Results Based on bioinformat-ics analysis,a total of 153 DEGs and 969 key module genes were identified.Based on the intersection of the above two re-sults,19 candidate genes were determined.Three machine learning algorithms identified four biomarkers[serum amyloid A2(SAA2),endoplasmic reticulum protein 27(ERP27),glutathione peroxidase 8(GPX8),and RAB protein family mem-ber RAB7B)],and the ROC curves confirmed that these four biomarkers have the ability to effectively distinguish DR pa-tients from healthy people.The nomogram model constructed based on these four biomarkers could effectively predict the probability of DR.Immune cell infiltration showed that these four biomarkers were significantly correlated with 28 immune cells.Drug prediction found that dexamethasone,glutathione disulfide and glutathione,which target SAA2 and GPX8,were potential drugs for DR treatment.Conclusion A reliable model for DR diagnosis can be established based on SAA2,ERP27,GPX8 and RAB7B,which are mainly involved in the complement and coagulation cascade,regulation of immune cell infiltration,and other key biological processes.

Ovarian cancer （OC） is one of the most common malignant tumors in women， with the mortality rate being the highest among gynaecological malignant tumors. As the atypical symptoms of OC are difficult to be detected in the early stage， most patients are already in the advanced stage when being diagnosed. As a result， the clinical treatment has limited effects. Currently， the main therapies for OC are surgery and chemotherapy， while their drug resistance and adverse reactions seriously reduce the quality of life of patients. In recent years， traditional Chinese medicine （TCM） has attracted the attention of clinicians and researchers because of its high efficacy， low toxicity， and mild side effects. According to the TCM philosophy of treatment based on syndrome differentiation， the Chinese medicines with multiple targets， wide range， and mild side effects can be screened based on the molecular targets involved in the occurrence and development of OC， which can bring out the unique advantages of TCM in the treatment of OC. Modern studies have shown that the occurrence and development of OC are closely related to the abnormal expression of multiple signaling pathways. The continued abnormal activation of the signal transducer and activator of transcription 3 （STAT3） signaling pathway can lead to abnormal proliferation and malignancy of OC. cause abnormal proliferation and malignant transformation of OC， which is closely related to the development of OC. In addition， studies have shown that Chinese medicine can inhibit the proliferation， angiogenesis， invasion， and metastasis and promote the autophagy and apoptosis of OC cells by regulating the Janus kinase 2 （JAK2）/STAT3 signaling pathway， providing new therapeutic strategies and ideas for the prevention and treatment of OC. This paper summarizes the role of JAK2/STAT3 signaling pathway in OC development by reviewing the relevant articles and reviews the mechanism and research progress of active components and compound prescriptions of Chinese medicine intervening in OC development by regulating the JAK2/STAT3 signaling pathway. This review is expected to provide a systematic reference for clinical research and drug development of OC.